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Abstract
Background: To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic
ventricular function.
Methods: 3304 patients with heart failure from 9 different studies were included (mean age 63 ± 14 years); out of
these, 711 subjects had preserved left ventricular ejection fraction (≥ 50%) and 994 patients in the whole cohort
suffered from diabetes.
Results: The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were
treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast,
patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p
< 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the
probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF
patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction
(p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class,
irrespective of renal function.
Conclusions: Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of
blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive
aldosterone receptor blocker therapy, irrespective of renal function.
Background
Heart failure is a major public health burden and the
lifetime risk of developing heart failure in a 40 year old
is around 20% [1]. About 50% of patients presenting
with heart failure have normal ejection fraction
(HFNEF) [2,3]. Recent research revealed that mortality
of hospitalized patients with HFNEF is comparable to
patients with systolic heart failure (SHF). However, in
most heart failure trials, HFNEF patients were largely
underrepresented.
Diabetes is a growing epidemiological burden and a
major contributor to cardiovascular disease. In male
patients with diabetes, the risk to develop heart failure
is doubled in comparison to non-diabetic patients, but it
is five times the risk of non-diabetic patients in women
[4]. Moreover, diabetes is an independent predictor of
poor outcome once SHF or HFNEF have developed
[5,6]. Current treatment guidelines provide evidence for
pharmacotherapy in diabetic patients with heart failure
and adherence to guidelines is associated with improved
outcome in both types of heart failure [7,8]. Of note, the
fore-mentioned guideline does not specifically address
patients with HFNEF [7].
The aim of the present study was to compare heart fail-
ure therapy in diabetic patients with SHF and HFNEF.
Methods
Patient cohorts
All subjects recruited within the German Heart Failure
Network are characterized by an extensive standardizes
baseline data set including information on socio-
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ogy and classification, cardiovascular risk factors,
comorbidities, medication, ECG, echocardiography, cor-
onary angiography, routine laboratory, and quality of life
[9]. In all studies, a uniform baseline data set was
obtained. All diagnostic procedures were performed in
accordance with pre-specified Standard Operating Pro-
cedures. All individual studies were approved by local
ethics committees.
For the current analysis, all patients from prospective
follow-up studies with a diagnosis of heart failure were
eligible.
In all patients echocardiography was performed
according to guidelines of the American Society of
Echocardiography (ASE) current at the time of data col-
lection, including targeted M-Mode and Doppler techni-
ques. All examinations were performed by physicians
experienced in the technique and a pre-specified stan-
dard operation procedure regarding echocardiography
was given. Preferable, the left ventricular ejection frac-
tion was determined using the Simpson’s model of discs.
If patient’s constitution did not allow sufficient appli-
ance of the Simpson’s method, visual estimation of
LVEF was permitted too. Patients were classified as hav-
ing SHF or HFNEF by echocardiographically determined
left ventricular ejection fraction using a cut-off of 50%.
Glomerular filtration rate was calculated by MDRD
formula [10].
Statistics
Data are presented as mean+/-SD or percentages. Esti-
mates of percent of patients receiving a certain substance
class are provided with 95% confidence intervals (CI).
Data were analysed by analysis of variance (quantita-
tive) and logistic regression (frequencies), both including
interaction terms for diabetes and left ventricular func-
tion. A two-tailed p < 0.05 was considered statistical sig-
nificant. SPSS 15 (SPSS Inc., Chicago, IL) was used for
analysis.
All individual studies were approved by local ethics
committees. The authors had full access to and take full
responsibility for the integrity of the data.
Results
Patient characteristics
3304 patients with heart failure from nine different sub-
studies were included into this analysis. In the total
sample, 711 patients (22%, 353 women) had preserved
ejection fraction and 2593 patients (78%, 653 women)
had SHF. 2310 patients (70%) were free of diabetes, 622
(19%) had mild diabetes (treated by diet or oral anti-
hyperglycemic drugs) and 372 (11%) had severe diabetes
(insulin-dependent treatment). Baseline characteristics of
the study cohort are also displayed in table 1, showing
significant differences for most variables according to
presence of diabetes or SHF. Except for the SF-36 score,
no significant interaction of effects of diabetes and ejec-
tion fraction was seen on all baseline variables.
Treatment
Overall, a high percentage of patients received the class
I recommended therapy (i.e., angiotensin converting
enzyme inhibitors [ACEi] or angiotensin-2 receptor-1
blocker [ARB] and beta-blockers). However, differences
were observed between HFNEF and SHF patients. Blood
p r e s s u r ec o n t r o li nH F N E Fw a sp o o r e rt h a ni nS H F ,
and was poorer in patients with diabetes than in
patients without diabetes (see table 1). There were also
differences how guideline-recommended substance
classes were applied in SHF and HFNEF for three
important sub-groups: Patients free of diabetes, patients
with mild diabetes and patients with severe diabetes [7].
As displayed in figure 1 around 90% of patients with
SHF received ACEi or ARB (panel A) and beta-blockers
(panel B) and neither the presence nor the severity
affected the treatment with these substance classes (p =
0.409 and p = 0.724, respectively). By contrast, the
intake of diuretics (figure 2, panel A) increased with the
presence and severity of diabetes (p < 0.001, respec-
tively) and a reduction in aldosterone receptor blocker
usage with diabetes (Figure 2, panel B) was observed
(p < 0.001).
A ss h o w ni nf i g u r e1 ,i nH F N E Ff e w e rp a t i e n t s
received ACEi/ARB therapy than in SHF (p < 0.001).
However, in contrast to SHF, both presence and the
severity of diabetes were associated with a higher intake
frequency of these substance classes (p < 0.001). A simi-
lar pattern was seen for beta-blockers (figure 1): The
intake in HFNEF was reduced, but increased with the
presence and severity of diabetes (p = 0.014). The pre-
sence of CAD was associated with a higher intake fre-
quency of beta-blockers in HFNEF, but not in SHF.
Comparable to SHF, diuretic therapy (figure 2) increased
with the presence and severity of diabetes (p < 0.001).
As also shown in figure 2, aldosterone receptor blockers
were administered with lower frequency in HFNEF (p <
0.001); this association was unaffected by the presence
and severity of diabetes (p = 0.198).
Role of comorbidities
We investigated in detail the associations between renal
dysfunction and the intake frequency of aldosterone
receptor blockers, since hyperkalemia due to spironolac-
tone poses a relevant risk in heart failure therapy [11].
Glomerular filtration rate was lower in SHF than in
H F N E Fa n dl o w e ri nd i a b e t i ct h a ni nn o n - d i a b e t i c
patients and was lower in diabetic SHF than in diabetics
HFNEF patients (see table 1). Figure 3 shows the
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stratified by preserved or reduced renal function and
t y p eo fh e a r tf a i l u r e .I nS H F ,t h ep e r c e n t a g eo f
patients receiving aldosterone receptor blockers
decreased with the presence and severity of diabetes.
Interestingly, this tendency was similar in patients
with reduced and preserved renal function. Moreover,
serum potassium levels were not different in patients
without and with diabetes (p = 0.756 for HFNEF, p =
0.162 for SHF).
In the whole sample, the intake of ACEi/ARB was
independently associated with the presence of diabetes,
hypertension and renal dysfunction. In contrast, the
intake of beta-blockers was associated with the presence
of coronary artery disease and hypertension.
Discussion
This is the first study to evaluate the most recent ESC/
EASD recommendations for heart failure therapy in a
large contemporary cohort of patients with heart failure.
Moreover, no previous paper has studied a comparably
high number of diabetic patients with heart failure and
normal ejection fraction (HFNEF).
Our study has three major findings:
(1) Around 90% of diabetic patients with SHF are
treated with ACEi/ARB and beta-blockers. This ther-
apy pattern is not different from patients without
diabetes.
(2) In contrast, diabetic patients with HFNEF are
less likely to receive ACEi/ARB and beta-blockers.
However, as compared to non-diabetic patients, they
are more likely to receive these therapies. Blood
pressure control in diabetic HFNEF patients is
poorer than in diabetic SHF patients.
(3) Irrespective of renal function, diabetic SHF
patients are less likely to receive aldosterone
antagonists.
Heart failure therapy in surveys
The percentage of patients with SHF receiving ACEi/
ARB and betablockers was close to 90% and, hence,
much higher than reported in previous surveys (e. g.,
the EuroHeart Survey) [12]. The large proportion of uni-
versity centres and the exclusive recruitment in cardiol-
ogy clinics may be an explanation [13]. An additional
possibility is that slowly but steadily we reach a better
implementation of guidelines in Germany.
Heart failure therapy in patients with diabetes
There are very few, if any, clinical trials on heart failure
treatment available that specifically address heart failure
with the comorbidity diabetes. Therefore, recent recom-
mendations carry a low level of evidence (level C) and
are derived from subgroup analyses of patients suffering
from diabetes in large heart failure trials [7]. In patients
with SHF, the use of ACEi/ARB, beta-blockers and
aldosterone antagonists have been shown to reduce
morbidity and mortality (for review, see [1]). Aldoster-
one antagonists reduce mortality in heart failure patients
with reduced ejection fraction and are of benefit in
patients with systolic heart failure and recent myocardial
infarction, with or without concomitant diabetes [14-16].
For HFNEF, there is yet no evidence-based drug-speci-
fic mortality reducing therapy available. Three trials
investigated the use of ACEi and ARBs in HFNEF
patients and failed to show a reduction in mortality
[17-19]. Other treatment str a t e g i e s ,e . g .a l d o s t e r o n e
receptor blockade, are currently investigated in clinical
trials. Tight blood pressure control is the only
Table 1 Baseline characteristics
No Diabetes (n = 2310) Diabetes (n = 994) P value for
respective effect
DM EF
EF <50% (n = 1769) EF ≥ 50% (n = 541) EF <50% (n = 824) EF ≥ 50% (n = 170)
Female (%) 23.5 49.2 28.9 51.2 0.005 <0.001
Age (years) 61.1 ± 14.3 63.1 ± 14.0 67.2 ± 10.3 69.4 ± 7.6 <0.001 <0.001
Body mass index (kg/m
2) 26.9 ± 4.5 28.5 ± 5.1 29.1 ± 5.5 30.3 ± 5.3 <0.001 <0.001
Heart rate (bpm) 73.0 ± 13.5 69.7 ± 12.7 74.2 ± 12.5 72.4 ± 14.4 0.004 <0.001
Systolic blood pressure (mmHg) 121 ± 19 138 ± 23 125 ± 19 140 ± 21 <0.001 <0.001
Diastolic blood pressure (mmHg) 73 ± 11 79 ± 12 73 ± 11 77 ± 13 0.076 <0.001
Glomerular filtration rate (mL/min) 72 ± 24 75 ± 22 64 ± 26 68 ± 24 <0.001 0.002
Hb (mmol/mL) 8.7 ± 1.1 8.7 ± 1.0 8.4 ± 1.2 8.3 ± 1.1 <0.001 0.644
SF-36 score 52 ± 28 59 ± 28 44 ± 28 44 ± 27 <0.001 0.020*
*Significant interaction (p = 0.015) between diabetes and ejection fraction.
￿DM: Diabetes mellitus, EF: ejection fraction.
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one would expect that this only recommendation would
be strictly followed. However, our study shows that
blood pressure control in HFNEF was inferior to SHF,
the difference of about 15 mmHg in systolic blood pres-
sure is partly explained by less pharmacotherapy.
The lack of evidence for heart failure treatment in
HFNEF might explain the lower use of ACEi/ARBs,
beta-blockers and aldosterone receptor blockers in
patients with HFNEF. In contrast, data from the
CHARM trial which was the largest trial to include
patients with both SHF and HFNEF, showed that the
presence of diabetes was of greater harm in HFNEF
than in SHF patients [20]. It is unknown whether a
more aggressive antihypertensive therapy develops bene-
fit in patients with HFNEF, but it has been shown that
diastolic dysfunction, a relevant pathophysiology in
HFNEF, is improved by lowering blood pressure [21].
We were recently able to show that diastolic dysfunction
is impaired along the whole diabetic continuum [22].
Furthermore, diastolic dysfunction, which is believed to
be the responsible mechanism for the development of
heart failure in the majority of patients with HFNEF, is
known to be found more frequent in diabetic patients
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Figure 1 Percentage of patients without diabetes (DM-), with mild diabetes (DM+, on diet or taking oral anti-hyperglycaemic drugs)
and with severe diabetes (DM++, insulin-dependent diabetes) receiving different drugs (mean, 95% confidence interval). Panel A
shows prevalence of treatment with ACE inhibitors or angiotensin receptor blockers, panel B shows therapy with beta-blockers. Data are
separated by ejection fraction: Left side preserved ejection fraction (EF ≥ 50%), right side reduced ejection fraction (EF <50%).
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in diabetes mellitus is thereby independent of renal
function and can also be found under effective glycae-
mic control [24,25]. Given the proposed association of
diabetes mellitus and blood pressure control with dia-
stolic dysfunction, we argue for an improvement of anti-
hypertensive therapy and of glycaemic control in
patients with HFNEF. However, the hypothesis that
strict blood pressure and glycaemic control is beneficial
in diabetic HFNEF patients should be tested in a pro-
spective randomised trial.
Role of comorbidities
The use of ACEi/ARB or spironolactone may cause
hyperkalemia, especially in patients with impaired renal
function. A large population-based study from Ontario
showed an increased incidence of hyperkalemia and sub-
sequent mortality after the publication of the RALES
trial and the rate of hyperkalemia in real-world is
thought to be much higher than in clinical trials for var-
ious reasons (e. g. less frequent assessment of electro-
lytes and renal function, higher dosage of medication)
[11,26,27]. In heart failure patients, diabetes has been
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Figure 2 Percentage of patients without diabetes (DM-), with mild diabetes (DM+, on diet or taking oral anti-hyperglycaemic drugs)
and with severe diabetes (DM++, insulin-dependent diabetes) receiving different drugs (mean, 95% confidence interval). Panel A
shows prevalence of treatment with diuretics, panel B shows therapy with aldosterone receptor blockers. Data are separated by ejection fraction:
Left side preserved ejection fraction (EF ≥ 50%), right side reduced ejection fraction (EF <50%).
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ment of hyperkalemia and severe hyperkalemia (asso-
ciated with hospitalization or death) [28,29]. Even with
impaired renal function, however, heart failure patients
with diabetes will benefit from ARB therapy and aldos-
terone receptor blockade, similarly to patients without
diabetes [28,29]. Our data from a clinical practice setting
suggest that the presence of the heart failure comorbid-
ity diabetes restrains doctors from prescribing evidence-
based therapy in heart failure patients - possibly in fear
of side-effects, although these side-effects can be easily
monitored by simple blood tests. As a consequence, we
suggest that diabetic heart failure patients should receive
appropriate doses of ACEi/ARB and/or aldosterone
receptor blockers under a tight control of potassium
and renal function markers, rather than withholding
these potentially life-saving drugs. Moreover, future
heart failure trials should focus on common comorbid-
ities in heart failure populations (diabetes, impaired
renal function, high age).
Limitations
This is a cross-sectional observational study and
although we included a high number of diabetic patients
with HFNEF, the majority of included diabetic patients
had SHF. In some of the studies, only patients with SHF
were included. Thus, a stricter guideline-adherence for
SHF in these SHF only studies may be an alternative
explanation for the observed differences to HFNEF ther-
apy. LVEF was not measured using a uniform methodol-
ogy and intra- and inter-observer variability was not
investigated and compared between the several medical
centres. Although in most of all included patients LVEF
was calculated according to Simpson’s method, this may
have biased our results.
Although we controlled for estimated glomerular fil-
tration rate, we cannot rule out that more patients with
diabetes had a history of acute renal failure and this
could partly explain the lower frequency of aldosterone
receptor intake in these patients.
Conclusions
Despite significant improvements in the pharmacother-
apy of heart failure, there is still a considerable under-
treatment in diabetic heart failure patients with HFNEF.
Diabetic SHF patients are less likely to receive aldoster-
one receptor blockade, irrespective of renal function and
potassium levels.
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